Viatris had declared only days ago that it was not anticipating introducing its proposed generic version of AstraZeneca’s Symbicort (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler until 2023.
This may change, however, after the company on 15 March scooped the first US Food and Drug Administration approval for...